


Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Canceled)

2. (Amended) A method for resensitizing ~~non-P-gp/non-MRP~~ S1-M1-3.2 multiple drug resistant cancer cells to treatment ~~with~~ with a chemotherapeutic agents agent to which said cancer cells have developed resistance comprising administration of an effective amount of a chemosensitizing reversal agent selected from compounds of Formula (I)



wherein:


n is an integer of 0, 1, or 2;

R¹ is hydrogen or alkoxy of 1 to 10 carbon atoms;

R² is hydrogen or alkenyl of 2 to 10 carbon atoms;

R³ is hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms,

R⁷NH(CH₂)_v– or




m is an integer of 1 to 6;


v is an integer of 1 to 4;

R⁴, R⁵ and R⁶ are hydrogen;

R⁷ is H or



R⁸ is selected from alkyl of 1 to 10 carbon atoms, -(CH₂)_mCO₂H,



or a pharmaceutically acceptable salt thereof, Fumitremorgin A, Fumitremorgin B and Fumitremorgin C and a chemotherapeutic agent resistant to said cancer cells.


3-4. (Cancelled)

5. (Original) The method according to claim 2 wherein the chemotherapeutic agent is selected from the group consisting of mitoxantrone, doxorubicin and topotecan.

6. (Amended) The method of ~~claim 3~~ claim 2 wherein the chemosensitizing reversal agent is administered prior to, concurrently with, or after administration of the chemotherapeutic agent.

7. (Canceled)

8. (Amended) A method for resensitizing BCRP-mediated multiple drug resistant cancer cells S1-M1-3.2 to treatment ~~with~~ with a chemotherapeutic agent ~~agents~~ to which said cancer cells have developed resistance comprising administration of an effective amount of a chemosensitizing reversal agent selected from compounds of Formula (I)



wherein:


n is an integer of 0, 1, or 2;

R¹ is hydrogen or alkoxy of 1 to 10 carbon atoms;

R² is hydrogen or alkenyl of 2 to 10 carbon atoms;

R³ is hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms,

R⁷NH(CH₂)_v– or




m is an integer of 1 to 6;


v is an integer of 1 to 4;

R⁴, R⁵ and R⁶ are hydrogen;

R⁷ is H or



R⁸ is selected from alkyl of 1 to 10 carbon atoms, -(CH₂)_mCO₂H,



or a pharmaceutically acceptable salt thereof, Fumitremorgin A, Fumitremorgin B and Fumitremorgin C and a chemotherapeutic agent resistant to said cancer cells.

9. (Cancelled)


10. (Amended) The method according to ~~claim 9~~ claim 8 wherein the chemotherapeutic agent is selected from the group consisting of mitoxantrone, doxorubicin, and topotecan.

11. (Cancelled)

12. (Amended) The method according to ~~claim 11~~ claim 8 wherein the chemosensitizing reversal agent is administered prior to, concurrently with, or after administration of the chemotherapeutic agent.

13-28. (Canceled)

29. (Amended) A method of reversing BCRP or other non P-gp/non MRP mediated resistance of cancer cells to chemotherapeutic agents in a mammal which comprises administration of an effective amount of a chemosensitizing reversal agent selected from compounds of Formula (I)



(I)

wherein:


n is an integer of 0, 1, or 2;

R¹ is hydrogen or alkoxy of 1 to 10 carbon atoms;

R² is hydrogen or alkenyl of 2 to 10 carbon atoms;

R³ is hydrogen, alkyl of 1 to 10 carbon atoms, alkenyl of 2 to 10 carbon atoms,

R⁷NH(CH₂)_v– or



m is an integer of 1 to 6;


v is an integer of 1 to 4;

R⁴, R⁵ and R⁶ are hydrogen;

R⁷ is H or



R⁸ is selected from alkyl of 1 to 10 carbon atoms, -(CH₂)_mCO₂H,



or a pharmaceutically acceptable salt thereof, Fumitremorgin A, Fumitremorgin B and Fumitremorgin C to a mammal to said mammal in need thereof having a BCRP or other non-P-gp/non MRP mediated resistant cancer and a chemotherapeutic agent to which said cancer cells are resistant.

30. (Cancelled)

31. (Original) The method according to claim 29 wherein the chemotherapeutic agent is selected from the group consisting of mitoxantrone, doxorubicin, and topotecan.

32. (Cancelled)

33. (Amended) The method according to ~~claim 32~~ claim 29 wherein the chemosensitizing reversal agent is administered prior to, concurrently with, or after administration of the chemotherapeutic agent.

34-63. (Canceled)